Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | CCR4 | P51679 | 2/20 | 0.33 |
| ▸ | KIT | P10721 | 2/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.33 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5216252 | 0.82 | ALOX5 (0.38) | TRPV1NPY5RMEN1KMT2AALOX5 | |
| SCHEMBL14422193 | 0.70 | MAPT (0.56) | TRPV1MEN1MAPTKMT2ANPSR1 | |
| SCHEMBL5215524 | 0.64 | POLB (0.44) | NPY5RMEN1GAAMAPTKMT2A | |
| SCHEMBL5221816 | 0.64 | POLB (0.44) | NPY5RGAAMAPTNPSR1 | |
| SCHEMBL5214660 | 0.64 | KIT (0.53) | OPRM1KIT | |
| SCHEMBL5214652 | 0.64 | KIT (0.52) | OPRM1KIT | |
| SCHEMBL26129788 | 0.64 | RAPGEF4 (0.56) | TRPV1MEN1MAPTKMT2ASRC | |
| SCHEMBL5215713 | 0.62 | ALDH1A1 (0.34) | TRPV1GAA | |
| SCHEMBL1889693 | 0.62 | RAB9A (0.66) | OPRM1MEN1GAAMAPTKMT2A | |
| SCHEMBL4926839 | 0.62 | L3MBTL1 (0.54) | OPRM1L3MBTL1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265138-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1818333-A1 | Vanilloid receptor ligands and their use in treatments | Amgen Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20040157845-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157845-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | TRPV1 1/4885OPRM1 156/4885NPY5R 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.